Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | GRM5 | P41594 | 10/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480910 | 1.00 | KCNH2 (0.57) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| SCHEMBL2895780 | 0.83 | GRM5 (0.73) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| SCHEMBL2895291 | 0.83 | GRM5 (0.73) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| SCHEMBL2895294 | 0.83 | GRM5 (0.73) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| SCHEMBL5483310 | 0.81 | KCNH2 (0.57) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| SCHEMBL5483665 | 0.78 | MEN1 (0.46) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| Azd2066 SCHEMBL1848325 | 0.77 | GRM5 (0.72) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| Azd2066 SCHEMBL1544607 | 0.77 | GRM5 (0.72) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| Azd2066 SCHEMBL4331565 | 0.77 | GRM5 (0.72) | KCNH2GRM5MAPK1MEN1ALDH1A1 | |
| Azd2066 SCHEMBL5053440 | 0.76 | GRM5 (0.71) | KCNH2GRM5MAPK1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRIN3A, GRM1 | KCNH2 527/4885GRM5 9/4885MAPK1 2437/4885 |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | KCNH2 453/4885GRM5 1/4885MAPK1 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.